														CI	OI	MS	F	OR	łМ
SUSPECT ADVERSE REACTION REPORT															_				
									П	T	Т	Т	Т	\top	Т	\top	Т	一	
															_	\perp			
I. REACTION INFO					MATION	1													
1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE (first, last) COSTA RICA Day Month Year 53					3. SEX 3a. WEIGHT 4-6 REACTION ONSET 8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION ADVERSE RE														
					Female kg MAR 2025 PATIENT DIED														
7 + 13 DESCRIBE REAC Event Verbatim [PREFER								 	_ ¬ ,	INVC	OLVED	OR	ť						
Stomachache [All stomach discomf		PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT																	
'viral episode' with Urinary infection		OR SIGNIFI DISABILITY							FICA Y OF	CANT OR									
anxiety for sweet things [Anxiety] 'viral episode' with diarrhea [Viral diarrhoea]						INCAPACITY LIFE THREATENING													
Ozempic adminis	stered in clicks [Wro	ong technique in produc		process]							ر	7 (CON	IGENIT		,			
	, .	unapproved indication]									-			MALY IER					
Case Description: ***This is an auto generated narrative*** (Continued on Additional Information Page)																			
II. SUSPECT DRUG(S) INFORMATION																			
14. SUSPECT DRUG(S) (include generic name) #1) Semaglutide B 1.34 mg/ml PDS290 1.0 mg (SEMAGLUTIDE 1.34 mg/ml					g/mL) Solution for injection, 1 mg 20. DID REACTION ABATE AFTER STOF DRUG?							OPPIN	NG						
					ROUTE(S) OF ADMINISTRATION) Subcutaneous					YES NO NA									
17. INDICATION(S) FOR #1) obesity (Obes		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?																	
` '					. THERAPY DURATION I) Unknown							YES	1 🔲	NO	\boxtimes	NA			
	III. CONCOMITANT DRUG(S) AND HISTORY																		
#1) ZOPICLONE	(ZOPICLONE);	MINISTRATION (exclude those use JUN-2025 / Ongoing	ed to treat re	eaction)															
#2) FLUOXETINE (FLUOXETINE) ; Ongoing #3) MELATONIN (MELATONIN) ; 2025 / Ongoing																			
- CTUED DELEVANT																			
23. OTHER RELEVANT From/To Dates Unknown to Ongo		, allergies, pregnancy with last mor Type of History / Notes Current Condition	·	Description	(Ohesity)														
]	Duration was not reported																		
Unknown to Origi	Unknown to Ongoing Current Condition Glucose tolerance impaired (Glucose tolerance impaired)																		
IV. MANUFACTURER INFORMATION																			
Novo Nordisk A/S						ned: I	No												
Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK					-														
Phone: +45 44448888																			
24b. MFR CONTROL NO.					25b. NAME AND ADDRESS OF REPORTER														
1475695					NAME AND ADDRESS WITHHELD.														
24c. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE STUDY LITERATURE																			
03-JUL-2025																			
DATE OF THIS REPORT																			

X INITIAL

FOLLOWUP:

Mfr. Control Number: 1475695

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Study ID: 199-NovoDia

Study description: Trial Title: Patient support programme to support physician and their daily work to maintain an optimal diabetic control of patients through added value services such as treatment starter kit, nutrition support through NovoDia call center, individual workshops, group workshops and free A1c test.

Patient's height: 154 cm.
Patient's weight: 123 kg.

Patient's BMI: 51.86372070.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Stomachache(Stomachache)" beginning on JUN-2025, "stomach discomfort.(Stomach discomfort)" beginning on JUN-2025, "viral episode' with high fevers(Fever)" beginning on JUN-2025, "Urinary infection(Urinary infection)" beginning on JUN-2025, "anxiety for sweet things(Anxiety)" beginning on JUN-2025, "viral episode' with diarrhea(Viral diarrhoea)" beginning on JUN-2025, "Ozempic administered in clicks(Wrong technique in product usage process)" beginning on MAR-2025, "Ozempic for obesity(Product use in unapproved indication)" beginning on MAR-2025 and concerned a 53 Years old Female patient who was treated with Ozempic 1.0 mg (SEMAGLUTIDE 1.34 mg/mL) from MAR-2025 and ongoing for "obesity",

Dosage Regimens:

Ozempic 1.0 mg: ??-MAR-2025 to Not Reported (Dosage Regimen Ongoing);

Current Condition: Obesity, Glucose tolerance impaired, circulatory problems, Insomnia.

Concomitant medications included - ZOPICLONE, FLUOXETINE, MELATONIN.

Treatment medications included - TRIMETHOPRIM, PHENAZOPYRIDINE HYDROCHLORIDE.

Batch Numbers:

Ozempic 1.0 mg: UNK;

Action taken to Ozempic 1.0 mg was reported as No Change.

On JUN-2025 the outcome for the event "Stomachache(Stomachache)" was Recovered.

On JUN-2025 the outcome for the event "stomach discomfort.(Stomach discomfort)" was Recovered.

On JUN-2025 the outcome for the event "'viral episode' with high fevers(Fever)" was Recovered.

The outcome for the event "Urinary infection(Urinary infection)" was Recovering/resolving.

The outcome for the event "anxiety for sweet things(Anxiety)" was Not recovered.

On JUN-2025 the outcome for the event "'viral episode' with diarrhea(Viral diarrhoea)" was Recovered.

The outcome for the event "Ozempic administered in clicks(Wrong technique in product usage process)" was Not recovered.

The outcome for the event "Ozempic for obesity(Product use in unapproved indication)" was Not recovered.

Reporter's causality (Ozempic 1.0 mg) - Stomachache(Stomachache): Unlikely

stomach discomfort.(Stomach discomfort): Unlikely 'viral episode' with high fevers(Fever): Unlikely Urinary infection(Urinary infection): Unlikely anxiety for sweet things(Anxiety): Unlikely

'viral episode' with diarrhea(Viral diarrhoea): Unlikely

Ozempic administered in clicks(Wrong technique in product usage process): Unknown

Ozempic for obesity(Product use in unapproved indication) : Unknown

Company's causality (Ozempic 1.0 mg) -

Stomachache(Stomachache): Possible

stomach discomfort.(Stomach discomfort): Possible 'viral episode' with high fevers(Fever): Unlikely Urinary infection(Urinary infection): Unlikely anxiety for sweet things(Anxiety): Unlikely

'viral episode' with diarrhea(Viral diarrhoea): Unlikely

Ozempic administered in clicks(Wrong technique in product usage process): Possible

Ozempic for obesity(Product use in unapproved indication): Possible

Mfr. Control Number: 1475695

ADDITIONAL INFORMATION

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Disorder circulatory system (Cardiovascular disorder);
Unknown to Ongoing	Current Condition	Insomnia (Insomnia);